South Dakota Investment Council lessened its holdings in Abbott Laboratories (NYSE:ABT) by 6.7% during the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 225,709 shares of the healthcare product maker’s stock after selling 16,100 shares during the quarter. South Dakota Investment Council’s holdings in Abbott Laboratories were worth $10,972,000 as of its most recent filing with the Securities & Exchange Commission.

Other institutional investors have also made changes to their positions in the company. Villere ST Denis J & Co. LLC grew its position in Abbott Laboratories by 2.3% in the 2nd quarter. Villere ST Denis J & Co. LLC now owns 268,200 shares of the healthcare product maker’s stock valued at $13,037,000 after acquiring an additional 5,950 shares during the last quarter. Private Bank & Trust Co. lifted its holdings in shares of Abbott Laboratories by 12.3% in the 2nd quarter. Private Bank & Trust Co. now owns 30,322 shares of the healthcare product maker’s stock worth $1,473,000 after buying an additional 3,330 shares during the period. Gratus Capital LLC lifted its holdings in shares of Abbott Laboratories by 0.9% in the 2nd quarter. Gratus Capital LLC now owns 205,067 shares of the healthcare product maker’s stock worth $9,968,000 after buying an additional 1,869 shares during the period. Comerica Securities Inc. purchased a new stake in shares of Abbott Laboratories in the 1st quarter worth $2,833,000. Finally, AQR Capital Management LLC lifted its holdings in shares of Abbott Laboratories by 264.8% in the 1st quarter. AQR Capital Management LLC now owns 634,391 shares of the healthcare product maker’s stock worth $28,173,000 after buying an additional 460,477 shares during the period. 71.10% of the stock is currently owned by institutional investors.

Shares of Abbott Laboratories (NYSE ABT) opened at $55.58 on Thursday. The company has a debt-to-equity ratio of 0.72, a quick ratio of 2.26 and a current ratio of 2.69. The firm has a market capitalization of $97,508.47, a price-to-earnings ratio of 23.25, a P/E/G ratio of 2.10 and a beta of 1.06. Abbott Laboratories has a 12 month low of $37.38 and a 12 month high of $56.69.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings data on Wednesday, October 18th. The healthcare product maker reported $0.66 earnings per share for the quarter, topping analysts’ consensus estimates of $0.65 by $0.01. The firm had revenue of $6.83 billion during the quarter, compared to analysts’ expectations of $6.72 billion. Abbott Laboratories had a return on equity of 13.98% and a net margin of 8.37%. The firm’s quarterly revenue was up 28.8% on a year-over-year basis. During the same period in the prior year, the business posted $0.59 EPS. analysts anticipate that Abbott Laboratories will post 2.49 earnings per share for the current fiscal year.

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, November 15th. Investors of record on Friday, October 13th were paid a dividend of $0.265 per share. This represents a $1.06 dividend on an annualized basis and a dividend yield of 1.91%. The ex-dividend date of this dividend was Thursday, October 12th. Abbott Laboratories’s dividend payout ratio (DPR) is currently 83.47%.

In other Abbott Laboratories news, EVP Daniel Gesua Sive Salvadori sold 96,603 shares of the stock in a transaction dated Monday, October 23rd. The stock was sold at an average price of $56.21, for a total value of $5,430,054.63. Following the completion of the sale, the executive vice president now directly owns 142,082 shares in the company, valued at $7,986,429.22. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider Alejandro D. Wellisch sold 2,153 shares of the stock in a transaction dated Wednesday, November 22nd. The shares were sold at an average price of $55.86, for a total value of $120,266.58. Following the completion of the sale, the insider now owns 10,256 shares of the company’s stock, valued at $572,900.16. The disclosure for this sale can be found here. Insiders have sold a total of 308,939 shares of company stock valued at $16,835,789 over the last 90 days. 0.76% of the stock is currently owned by company insiders.

Several equities research analysts have weighed in on ABT shares. Jefferies Group reiterated a “buy” rating and issued a $58.00 target price on shares of Abbott Laboratories in a report on Thursday, August 3rd. Stifel Nicolaus upped their target price on Abbott Laboratories from $58.00 to $63.00 and gave the stock a “buy” rating in a report on Thursday, October 19th. BMO Capital Markets reiterated a “hold” rating and issued a $53.00 target price on shares of Abbott Laboratories in a report on Friday, September 1st. Zacks Investment Research upgraded Abbott Laboratories from a “hold” rating to a “buy” rating and set a $61.00 target price for the company in a report on Tuesday, October 31st. Finally, Cowen reiterated a “buy” rating and issued a $55.00 target price on shares of Abbott Laboratories in a report on Thursday, August 17th. Seven investment analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $56.81.

TRADEMARK VIOLATION NOTICE: “Abbott Laboratories (ABT) Shares Sold by South Dakota Investment Council” was reported by Daily Political and is the sole property of of Daily Political. If you are viewing this news story on another website, it was stolen and reposted in violation of US & international copyright and trademark legislation. The legal version of this news story can be accessed at https://www.dailypolitical.com/2017/11/30/abbott-laboratories-abt-shares-sold-by-south-dakota-investment-council.html.

About Abbott Laboratories

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The Company operates through four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. Its Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.

Want to see what other hedge funds are holding ABT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Abbott Laboratories (NYSE:ABT).

Institutional Ownership by Quarter for Abbott Laboratories (NYSE:ABT)

Receive News & Ratings for Abbott Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Abbott Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.